| 1 |
Which of the following best describes the concept of "beat perception" as it relates to the auditory capabilities of newborn infants?
|
The extraction of a consistent rhythm from a sequence of sounds. |
|
because in the current exprtiment has established that newborn infants are capable of beat based processing
|
the conclusions of Winker et al.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
According to the research, what experimental method is used to differentiate beat perception from statistical learning in newborns?
|
Monitoring brain activity using EEG during auditory stimulation. |
|
manipulated the isochrony of sound sequences in order to disentangle statistical learning from beat perception in sleeping newborn infants in ann EEG experiment
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does the mismatch response (MMR) in EEG studies indicate about newborns' auditory processing?
|
Difficulty in distinguishing between different sound frequencies. |
|
found for diffirent metrical positions were based on learning the statistical properties of the order of diffirent tones
|
Bouwer et al.,2014
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
What does the term "statistical learning" refer to in the context of auditory processing in newborns?
|
Extraction of regularities from the order of sounds without explicit feedback. |
|
Statistical learning in its narrowest sense is the extraction of these regularities from the order of the elements of the input without explicit feedback or even awareness after prolonged exposure
|
Conway,2020
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
Which condition in the EEG study did NOT result in a differentiation between beat and offbeat responses in newborns?
|
Harmonic condition. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
Which neural mechanism is thought to underlie the synchronization of movement to a beat?
|
Cognitive dissonance reduction. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
How does beat perception in newborns relate to their later musical abilities?
|
It is fundamental for developing rhythmic coordination and timing. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What is the primary purpose of using EEG in studies of auditory processing in newborns?
|
To record brain responses to sounds. |
|
we manipulated the isochrony of sound sequences in order to disentangle statistical learning from beat perception in sleeping newborn infants in an EEG experiment,
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
What does an isochronous condition in an auditory study typically involve?
|
A consistent temporal interval between sounds. |
|
sochronous condition, sounds are presented with a constant inter-onset interval (IOI), allowing a beat to be induced
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
Which auditory feature is NOT directly studied in the newborn auditory processing research?
|
Language comprehension. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What term is used to describe the appearance of scientific credibility used in the marketing of unproven cell-based therapies?
|
Scientific consensus |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
According to the article, which of the following is NOT a recognized reporting mechanism for adverse effects from cell and gene therapies?
|
MedWatch by the FDA |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What ethical consideration is primarily challenged by direct-to-consumer marketing of unproven cell and gene therapies?
|
Allocation of healthcare resources |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What key feature differentiates proven CGT products from unproven ones according to regulatory standards?
|
All of the above |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
Which of the following is a risk associated with unproven CGT products highlighted in the article?
|
Lower costs compared to conventional treatments |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which of the following is NOT a typical characteristic of unproven CGT products as discussed in the article?
|
Lack of pre-clinical data |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
How do regulatory bodies like the FDA and EMA ensure the safety of CGT products?
|
By requiring rigorous pre-marketing clinical trials |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What is the primary goal of the ISCT's position on cell and gene therapies as mentioned in the article?
|
To support evidence-based products and oppose unproven ones |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What is a potential consequence for patients using unproven CGT products?
|
Risk of serious adverse effects |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What role does the ISCT play in the context of cell and gene therapies?
|
It opposes the premature commercialization of unproven therapies. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|